Short-term and long-term outcomes of submucosal dissection for residual or recurrent colorectal tumors after endoscopic resection: Analysis of a multicenter prospective study.

endoscopic submucosal dissection recurrent colorectal tumor residual colorectal tumor

Journal

Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
ISSN: 1443-1661
Titre abrégé: Dig Endosc
Pays: Australia
ID NLM: 9101419

Informations de publication

Date de publication:
26 Dec 2023
Historique:
received: 27 06 2023
accepted: 25 12 2023
medline: 27 12 2023
pubmed: 27 12 2023
entrez: 26 12 2023
Statut: aheadofprint

Résumé

We previously demonstrated that a favorable long-term prognosis indicated that endoscopic submucosal dissection (ESD) could be the standard treatment for large colorectal epithelial neoplasms, but the usefulness of ESD for local residual or recurrent tumors with submucosal fibrosis has not been fully demonstrated. The aim of the present study was to assess the usefulness of ESD for local residual or recurrent colorectal tumors. We conducted a nationwide multicenter prospective study to evaluate the outcomes of ESD for colorectal tumors. In this post-hoc analysis, a total of 54 local residual or recurrent colorectal tumors in 54 patients were included, and we analyzed the short-term and long-term outcomes of ESD for these lesions. The median size of the lesions was 16.0 (IQR;11-25) mm. ESD was completed in 53 cases (98.1%) with a median procedure time of 65.0 min, but it was discontinued in one case due to submucosal cancer invasion. En-bloc resection was achieved in 52 cases (96.3%), while R0 resection was achieved in 45 cases (83.3%). Intraoperative perforation was observed in 4 cases (7.4%) and delayed perforation in 1 case (1.9%), but all cases could be managed conservatively. Delayed bleeding was not observed. There were no significant differences in short-term outcomes between the rectal and colonic lesions. There was no recurrence of the tumor during the median follow-up period of 60 months (IQR 50-64). An analysis of our multicenter prospective study suggests that ESD is an effective salvage management for local residual or recurrent colorectal lesions.

Sections du résumé

BACKGROUND BACKGROUND
We previously demonstrated that a favorable long-term prognosis indicated that endoscopic submucosal dissection (ESD) could be the standard treatment for large colorectal epithelial neoplasms, but the usefulness of ESD for local residual or recurrent tumors with submucosal fibrosis has not been fully demonstrated. The aim of the present study was to assess the usefulness of ESD for local residual or recurrent colorectal tumors.
METHODS METHODS
We conducted a nationwide multicenter prospective study to evaluate the outcomes of ESD for colorectal tumors. In this post-hoc analysis, a total of 54 local residual or recurrent colorectal tumors in 54 patients were included, and we analyzed the short-term and long-term outcomes of ESD for these lesions.
RESULTS RESULTS
The median size of the lesions was 16.0 (IQR;11-25) mm. ESD was completed in 53 cases (98.1%) with a median procedure time of 65.0 min, but it was discontinued in one case due to submucosal cancer invasion. En-bloc resection was achieved in 52 cases (96.3%), while R0 resection was achieved in 45 cases (83.3%). Intraoperative perforation was observed in 4 cases (7.4%) and delayed perforation in 1 case (1.9%), but all cases could be managed conservatively. Delayed bleeding was not observed. There were no significant differences in short-term outcomes between the rectal and colonic lesions. There was no recurrence of the tumor during the median follow-up period of 60 months (IQR 50-64).
CONCLUSION CONCLUSIONS
An analysis of our multicenter prospective study suggests that ESD is an effective salvage management for local residual or recurrent colorectal lesions.

Identifiants

pubmed: 38148178
doi: 10.1111/den.14752
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

This article is protected by copyright. All rights reserved.

Auteurs

Hirohito Tanaka (H)

Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Gunma, Japan.
Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan.

Toshio Uraoka (T)

Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Gunma, Japan.
Division of Research and Development for Minimally Invasive Treatment, Cancer Center, Keio University School of Medicine, Tokyo, Japan.

Nozomu Kobayashi (N)

Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
Department of Gastroenterology, Tochigi Cancer Center, Tochigi, Japan.

Ken Ohata (K)

Department of Gastroenterology, NTT Medical Center, Tokyo, Japan.

Yoji Takeuchi (Y)

Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Gunma, Japan.
Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.

Akiko Chino (A)

Division of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.

Masayoshi Yamada (M)

Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.

Yosuke Tsuji (Y)

Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Kinichi Hotta (K)

Division of Endoscopy, Shizuoka Cancer Center, Shizuoka, Japan.

Keita Harada (K)

Department of Gastroenterology, Okayama University Hospital, Okayama, Japan.

Hiroaki Ikematsu (H)

Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Chiba, Japan.

Takashi Murakami (T)

Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan.

Shigetsugu Tsuji (S)

Department of Gastroenterology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan.

Atsushi Katagiri (A)

Division of Gastroenterology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.

Shinichiro Hori (S)

Department of Gastroenterology, NHO Shikoku Cancer Center, Ehime, Japan.
Department of Gastrointestinal Medicine, Japan Red Cross Society Himeji Hospital, Hyogo, Japan.

Tomoki Michida (T)

Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.
Department of Internal Medicine, Japan Community Healthcare Organization Osaka Hospital, Osaka, Japan.

Takuto Suzuki (T)

Department of Gastroenterology, Chiba Cancer Center, Chiba, Japan.

Masakatsu Fukuzawa (M)

Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan.

Shinsuke Kiriyama (S)

Department of Surgery, Japan Community Healthcare Organization Gunma Central Hospital, Gunma, Japan.

Kazutoshi Fukase (K)

Department of Internal Medicine, Yamagata Prefectural Central Hospital, Yamagata, Japan.
Department of Internal Medicine, Yamagata Prefectural Kahoku Hospital, Yamagata, Japan.

Yoshitaka Murakami (Y)

Department of Medical Statistics, Toho University, Tokyo.

Hideki Ishikawa (H)

Department of Molecular-Targeting Cancer Prevention, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Akihito Nagahara (A)

Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan.

Yutaka Saito (Y)

Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.

Classifications MeSH